Last reviewed · How we verify
Investigator's Choice of Therapy
Investigator's Choice of Therapy is a Small molecule drug developed by Zai Lab (Shanghai) Co., Ltd.. It is currently in Phase 3 development.
Investigator's Choice of Therapy is a flexible treatment approach where the treating physician selects from approved or standard-of-care therapeutic options based on individual patient characteristics.
At a glance
| Generic name | Investigator's Choice of Therapy |
|---|---|
| Sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This is not a single drug entity but rather a study arm design commonly used in clinical trials, particularly in oncology and other therapeutic areas. It allows investigators to choose the most appropriate standard treatment for each patient, serving as a comparator arm to evaluate investigational therapies. The specific mechanism depends entirely on which therapy the investigator selects.
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (PHASE3)
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigator's Choice of Therapy CI brief — competitive landscape report
- Investigator's Choice of Therapy updates RSS · CI watch RSS
- Zai Lab (Shanghai) Co., Ltd. portfolio CI